RE: RE: Urocidin P3 ended with Endo ! If you all recall, us posters could never really figure out why Endo went in to this trial in the first place. BCG was the placebo that we needed to compare to, and we did this at the refractory level.
Mitomycin wasn't part of the original protocol and it didn't appear necessary. It can't be a product of high demand. Now they couldn't even recruit enough people to compare Urocidin to Mitomycin. Maybe there not many people doing Mitomycin. From my readings, it doesn't appear to be something that seems too attractive to use. Do they have any useful data from the testing to date? If not, then all this trial ended up doing is delaying the process for 18 months. Hence: No milestone payments.
I'm not totally surprised, but I am disappointed
TC9